ArticleBioSocieties2022
Value-creation in the health data domain: a typology of what health data help us do.
Article in BioSocieties, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Digital Public Reporting Systems for Evaluating Health Care Quality: Systematic Review.JMIR medical informatics · 2026Pooled it
- Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?Journal of medical Internet research · 2026Article
- What patients value in data reuse for oncology research: a multi-stakeholder qualitative study to inform the European Health Data Space implementation in Belgium and beyond.Archives of public health = Archives belges de sante publique · 2026Article
- Ethical considerations for multimodal artificial intelligence in healthcare.AI and ethics · 2026Article
- Big Data, Machine Learning, and Personalization in Health Systems: Ethical Issues and Emerging Trade-Offs.Science and engineering ethics · 2025Article
- Ethical considerations on the use of big data and artificial intelligence in kidney research from the ERA ethics committee.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Ethical and social implications of public-private partnerships in the context of genomic/big health data collection.European journal of human genetics : EJHG · 2024Article
- Wearable Technologies for Healthy Ageing: Prospects, Challenges, and Ethical Considerations.The Journal of frailty & aging · 2024Article
- Wearable Technologies and Stress: Toward an Ethically Grounded Approach.International journal of environmental research and public health · 2023Article
- Digital Twins in Translational Research and Health Care: An Anthropological Perspective.Ethics & human researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has become a trope to speak of the increasing value of health data in our societies. Such rhetoric is highly performative: it creates expectations, channels and justifies investments in data technologies and infrastructures, and portrays deliberations on political and legal issues as obstacles to the flow of data. Yet, important epistemic and political questions remain unexamined, such as how the value of data is created, what data journeys are envisioned by policies and regulation, and for whom data types are (intended to be) valuable. Drawing on two empirical cases, (a) interviews with physicians on the topic of digital selfcare, and (b) expectations of stakeholders on the use of Real-World Data in clinical trials, as well as existing literature, we propose a typology of what health data help us to do. This typology is intended to foster reflection about the different roles and values that data use unfolds. We conclude by discussing how regulation can better accommodate practices of valuation in the health data domain, with a particular focus on identifying regulatory challenges and opportunities for EU-level policy makers, and how Covid-19 has shed light on new aspects of each case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.